J. McGinnis

发表

Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration

J. Mccombs, I. Tonnu-Mihara, D. Fox, 2017, Journal of gastroenterology and hepatology.

The Impact of Delayed Hepatitis C Viral Load Suppression on Patient Risk: Historical Evidence from the Veterans Administration

J. Mccombs, T. Matsuda, I. Tonnu-Mihara, 2016, Forum for health economics & policy.

Comparison of Health Services Use Associated with Ziprasidone and Olanzapine among Schizophrenia and Bipolar Disorder Patients in the USA

Yawen Jiang, W. Ni, J. McGinnis, 2014, Clinical Drug Investigation.

The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials

R. Coleman, A. Ganti, J. Baranda, 2021, Oncology.

Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013

J. McLaughlin, Joseph Fortuna, J. McGinnis, 2015, The Journal of Primary Prevention.

Treatment of patients waitlisted for liver transplant with all‐oral direct‐acting antivirals is a cost‐effective treatment strategy in the United States

S. Saab, Z. Younossi, G. Cholankeril, 2017, Hepatology.

Can hepatitis c treatment be safely delayed?: evidence from the veterans administration healthcare system

T. Matsuda, I. Tonnu-Mihara, J. McGinnis, 2015 .

O003 : Can hepatitis c treatment be safely delayed? evidence from the veterans administration healthcare system

J. Mccombs, T. Matsuda, I. Tonnu-Mihara, 2015 .

Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials.

D. Camidge, Y. Zakharia, Haeseong Park, 2021, Future oncology.